$85m fund supports monoclonal antibody for fibro-inflammatory disorders

Monoclonal antibodies

Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing.

The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer.

The clinical programme for LASN01 is focused primarily in TED with a cohort in idiopathic pulmonary fibrosis (IPF).

Lassen recently presented data using orbital fibroblast cells from TED patients demonstrating that LASN01 suppresses multiple markers associated with TED disease progression including hyaluronan production, cell proliferation and other markers such as procollagen.

“I am very pleased with the recent advancements at Lassen, particularly in successfully concluding the Series B financing round which will facilitate the continued development of our two pipeline products,” said Maria Fardis, Chief Executive Officer of Lassen.

“The proceeds allow us to advance LASN01 Phase I and II clinical programmes and develop a subcutaneous formulation for LASN01. This antibody has significant potential as a treatment for fibro-inflammatory disorders including TED. Our data in orbital fibroblasts have been highly encouraging and paired with our Phase I single and multiple ascending dose safety data, support advancement of LASN01 in Phase II for TED.”

LASN01 is a first-in-class monoclonal antibody targeting the receptor for IL-11 (IL-11R). Monoclonal antibody LASN500 targes the IL-18 binding protein (IL-18BP). IL-18BP is elevated at the tumour site in multiple cancer indications and blockade of this protein allows for elevation of IL-18 at the tumour site, which is expected to provide a better safety profile.

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free